Andrew P Barbour

List of Publications by Year
in descending order

79 papers	12,267 citations	136950 32 h-index	66911 78 g-index
82 all docs	82 docs citations	82 times ranked	17788 citing authors

#	Article	IF	Citations
1	Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Gastroenterology, 2022, 162, 320-324.e4.	1.3	26
2	qmotif: determination of telomere content from whole-genome sequence data. Bioinformatics Advances, 2022, 2, .	2.4	5
3	C5b-9 Membrane Attack Complex Formation andÂExtracellular Vesicle Shedding in Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Frontiers in Immunology, 2022, 13, 842023.	4.8	4
4	Elevation of fatty acid desaturaseÂ2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acidâ€induced DNA damage. Clinical and Translational Medicine, 2022, 12, e810.	4.0	6
5	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	1.3	90
6	Human CD141⁺ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. , 2021, 9, e001963.		25
7	Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches. Cancer Treatment Reviews, 2021, 98, 102219.	7.7	4
8	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer, 2021, 21, 936.	2.6	12
9	Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. JAMA Surgery, 2021, 156, 836.	4.3	41
10	ROR1 and ROR2 expression in pancreatic cancer. BMC Cancer, 2021, 21, 1199.	2.6	4
11	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Practical Radiation Oncology, 2020, 10, e136-e146.	2.1	41
12	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 2020, 10, 17687.	3.3	14
13	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. European Journal of Surgical Oncology, 2020, 46, 2140-2146.	1.0	8
14	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	6.4	78
15	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. Annals of Surgical Oncology, 2020, 27, 1420-1429.	1.5	10
16	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324.	2.4	0
17	Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. Theranostics, 2020, 10, 4116-4133.	10.0	23
18	To BE or not to BE: non-invasive screening for Barrettâ€™s esophagus, dysplasia and adenocarcinoma. Translational Gastroenterology and Hepatology, 2019, 4, 31-31.	3.0	1

#	Article	IF	Citations
19	The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 2375-2384.	1.5	16
20	Complex structural rearrangements are present in high-grade dysplastic Barrettâ€™s oesophagus samples. BMC Medical Genomics, 2019, 12, 31.	1.5	19
21	Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. European Journal of Surgical Oncology, 2019, 45, 832-837.	1.0	4
22	Patients with inâ€transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PVâ€10â€”A propensity score matched, single center study. Journal of Surgical Oncology, 2019, 119, 717-727.	1.7	1
23	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology, 2018, 68, 949-963.	7.3	106
24	Neoadjuvant therapy reduces cardiopulmunary function in patients undegoing oesophagectomy. International Journal of Surgery, 2018, 53, 86-92.	2.7	17
25	Intralesional PVâ€10 for the treatment of inâ€transit melanoma metastasesâ€”Results of a prospective, nonâ€randomized, single center study. Journal of Surgical Oncology, 2018, 117, 579-587.	1.7	30
26	Breaking bad conduits: â€˜resleevingâ€™ the intrathoracic gastric conduit post oesophagectomy. ANZ Journal of Surgery, 2018, 88, E222-E223.	0.7	0
27	Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Journal of Surgical Oncology, 2018, 117, 1687-1696.	1.7	20
28	Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus. Molecular and Cellular Proteomics, 2018, 17, 2324-2334.	3.8	25
29	Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma. ANZ Journal of Surgery, 2017, 87, 44-48.	0.7	20
30	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	27.8	716
31	Primary cutaneous melanoma of the scalp: Patterns of recurrence. Journal of Surgical Oncology, 2017, 115, 449-454.	1.7	16
32	When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the â€˜Australian guidelines for the management of cutaneous melanomaâ€™. Australasian Journal of Dermatology, 2017, 58, 274-277.	0.7	12
33	Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study. Annals of Surgical Oncology, 2017, 24, 3245-3251.	1.5	16
34	Long-term Health-related Quality of Life Following Esophagectomy. Annals of Surgery, 2017, 265, 1158-1165.	4.2	38
35	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	1.3	174
36	Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. Medical Journal of Australia, 2016, 204, 419-422.	1.7	14

#	Article	IF	Citations
37	Molecular markers to complement sentinel node status in predicting survival in patients with high-risk locally invasive melanoma. International Journal of Cancer, 2016, 139, 664-672.	5.1	7
38	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nature Genetics, 2016, 48, 1131-1141.	21.4	332
39	Glyco-centric lectin magnetic bead array (LeMBA) â^' proteomics dataset of human serum samples from healthy, Barrett×³s esophagus and esophageal adenocarcinoma individuals. Data in Brief, 2016, 7, 1058-1062.	1.0	6
40	Australian Multicenter Study of Isolated Limb Infusion for Melanoma. Annals of Surgical Oncology, 2016, 23, 1096-1103.	1.5	43
41	Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis, 2016, 37, 356-365.	2.8	46
42	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	27.8	2,700
43	Prospective study of patterns of surgical management in adults with primary cutaneous melanoma at high risk of spread, in Queensland, Australia. Journal of Surgical Oncology, 2015, 112, 359-365.	1.7	27
44	Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. Psycho-Oncology, 2015, 24, 763-770.	2.3	49
45	Two cases of <scp>NSAID</scp>â€induced gastropathy and enteropathy of the ileum. ANZ Journal of Surgery, 2015, 85, 584-585.	0.7	1
46	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	27.8	2,132
47	Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?. Annals of Surgical Oncology, 2015, 22, 4052-4059.	1.5	10
48	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. EBioMedicine, 2015, 2, 671-680.	6.1	86
49	Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma. Molecular and Cellular Proteomics, 2015, 14, 3023-3039.	3.8	33
50	MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. Pigment Cell and Melanoma Research, 2015, 28, 254-266.	3.3	59
51	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. Journal of Clinical Oncology, 2015, 33, 4115-4115.	1.6	5
52	A Case-Control Study of the Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma in Australia. Journal of Oncology, 2014, 2014, 1-7.	1.3	6
53	Controversies in the management of gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 216-227.	1.1	6
54	Australian multiâ€center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. Journal of Surgical Oncology, 2014, 109, 780-785.	1.7	23

#	Article	IF	Citations
55	Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes. Gastric Cancer, 2014, 17, 152-160.	5.3	12
56	Genomeâ€wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis. Genes Chromosomes and Cancer, 2014, 53, 324-338.	2.8	38
57	Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nature Communications, 2014, 5, 5224.	12.8	236
58	BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy. European Journal of Cancer, 2014, 50, 2668-2676.	2.8	67
59	Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy. European Journal of Cancer, 2014, 50, 1301-1309.	2.8	24
60	Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome. International Journal of Cancer, 2013, 133, 3000-3007.	5.1	14
61	Early Diagnostic Biomarkers for Esophageal Adenocarcinomaâ€"The Current State of Play. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1185-1209.	2.5	29
62	Role of human papillomaviruses in esophageal squamous cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 12-28.	1.1	27
63	Surgical management in patients with pancreatic cancer: a <scp>Q</scp>ueensland perspective. ANZ Journal of Surgery, 2013, 83, 859-864.	0.7	6
64	An innovative approach for locally advanced stage III cutaneous melanoma. Melanoma Research, 2012, 22, 257-262.	1.2	13
65	Clinical issues in oesophageal adenocarcinoma: could DNA copy number hold the key?. ANZ Journal of Surgery, 2012, 82, 599-606.	0.7	2
66	Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. Gastroenterology, 2012, 142, 1021-1031.e15.	1.3	443
67	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	27.8	1,741
68	Modeling the Cost-effectiveness of Strategies for Treating Esophageal Adenocarcinoma and High-grade Dysplasia. Journal of Gastrointestinal Surgery, 2012, 16, 1451-1461.	1.7	11
69	Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology, The, 2011, 12, 681-692.	10.7	1,467
70	Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. European Journal of Cancer, 2011, 47, 354-360.	2.8	300
71	Defining Cure for Esophageal Cancer: Analysis of Actual 5-Year Survivors Following Esophagectomy. Annals of Surgical Oncology, 2011, 18, 1766-1774.	1.5	46
72	Thoracoscopic-Assisted Esophagectomy for Esophageal Cancer. Annals of Surgery, 2010, 252, 281-291.	4.2	42

#	Article	IF	Citations
73	Risk Stratification for Early Esophageal Adenocarcinoma: Analysis of Lymphatic Spread and Prognostic Factors. Annals of Surgical Oncology, 2010, 17, 2494-2502.	1.5	86
74	Isolated Limb Infusion for Malignant Melanoma: Predictors of Response and Outcome. Annals of Surgical Oncology, 2009, 16, 3463-3472.	1.5	37
75	Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response. Annals of Surgical Oncology, 2008, 15, 2894-2902.	1.5	68
76	Consideration of Mesh-Related Complications. Annals of the Royal College of Surgeons of England, 2008, 90, 175-176.	0.6	1
77	Adenocarcinoma of the Gastroesophageal Junction. Annals of Surgery, 2007, 246, 1-8.	4.2	203
78	Endoscopic Ultrasound Predicts Outcomes for Patients with Adenocarcinoma of the Gastroesophageal Junction. Journal of the American College of Surgeons, 2007, 205, 593-601.	0.5	59
79	Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome. Annals of Surgical Oncology, 2007, 14, 306-316.	1.5	71